FDA Brief

Warning letters Drugs

FDA warning letter to

Unexo Lifesciences, Private Limited

High riskIssued Nov 6, 2024Posted Nov 19, 2024Center for Drug Evaluation and Research (CDER)

FDA warned Unexo Lifesciences over serious CGMP violations, including data integrity failures and torn batch records for U.S.-bound drugs.

What happened

FDA inspected Unexo's drug manufacturing facility from May 1 to 14, 2024. Investigators found torn batch production records in plastic bags on the rooftop, missing batch records for U.S.-market patches, records retrospectively prepared for the inspection, incomplete laboratory raw data, and computer controls that let a QC analyst manipulate results, dates, and COA stamp approvals. FDA also observed unclean air conditioner vents above production areas and said inspection access was limited when a computer was taken home and files were deleted from a laptop.

What FDA found

  1. The quality control unit did not adequately oversee data reliability and CGMP compliance.

    21 CFR 211.22
  2. Batch production and control records were incomplete, torn, missing, or retrospectively prepared for U.S.-market batches.

    21 CFR 211.188
  3. Laboratory records lacked complete raw data needed to support release testing.

    21 CFR 211.194(a)
  4. Computer system controls allowed an analyst to manipulate results, dates, and vendor stamp images on certificate of analysis records.

    21 CFR 211.68(b)
  5. Air conditioner vents above production areas were unclean, creating a contamination risk.

    21 CFR 211.67(a)
  6. FDA's access to records was limited when a computer was unavailable and files were deleted before review.

    section 501(j) of the FD&C Act

What FDA wants

FDA asks Unexo to provide a comprehensive data integrity investigation, risk assessment, CAPA plan, documentation and quality unit assessments, cleaning assessment and CAPA, and a recall update within 15 working days; it also asks the firm to notify FDA before resuming U.S. drug manufacturing.

Who should pay attention

  • U.S. distributors and pharmacies handling Unexo-made patches
  • companies sourcing drugs from Unexo
  • quality teams managing third-party COAs and electronic records

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natural Essentials, Inc.

    FDA warns Natural Essentials over OTC drug manufacturing violations, including inadequate failing test result investigations and missing component identity tests.

    High risk
  2. Pritam International Private Limited

    Pritam International, an Indian OTC drug maker, was cited for CGMP violations, falsified lab data, unsafe color additive, and DEG/EG testing gaps.

    High risk
  3. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk
  4. SnugZ USA, Inc.

    SnugZ USA, an OTC drug maker in West Jordan, Utah, was cited for releasing drugs after retesting failed batches until they passed.

    High risk